Nicholas Piramal

From Wikipedia, the free encyclopedia

This article (or section) may need to be wikified to meet Wikipedia's quality standards.
Please help improve this article, especially its section layout, and relevant internal links. (help)
This article has been tagged since February 2007.

This article or section is written like an advertisement.
Please help rewrite this article from a neutral point of view per Wikipedia policy.
Mark blatant advertising for speedy deletion with {{db-spam}}. (help, talk)

The neutrality of this article is disputed.
Please see the discussion on the talk page.

Nicholas Piramal India Limited (Nicholas Piramal India Limited (NPIL) is India's second largest Pharmaceutical Healthcare company with presence in the Cardio-vascular segment, Antibiotics and Respiratory segments, Pain management, Neuro-psychiatry and Anti-Diabetics segments and Biotechnology.For 2005-06, NPIL's recorded a turnover of Rs 14.1 billion and profits after tax were Rs 1.7 billion.

NPIL's brands in the pharma business are Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint - these bring in 67 per cent of the business, while its secondary brands which include Paraxin, Flagyl and Omnatax contribute around 24 % of its revenues.

NPIL came into existence in 1988 when it acquired Nicholas Laboratories from Sara Lee and in the last 15 years grown primarily on acquisitions, mergers and alliances. Some of NPIL's acquisitions include the Indian operations of Roche Products Ltd., Boehringer Mannheim India Ltd., Hoechst Marrion Roussel Ltd,'s Research Centre, Rhone Poulenc India Ltd., ICI India Ltd.'s Pharma Division and Aventis' Research facilities.

NPIL has joint ventures and alliances with F. Hoffmann-La Roche Ltd., Switzerland; Allergan Inc., USA; UK; Gilead Sciences, USA; Cheissi, Italy; and IVAX Corp; UK.

NPIL's has a 2700-strong field force. NPIL, together with its JVs, has 16 strong brands in the Indian Pharma Industry; manufacturing plants - NPIL has plants in Hyderabad and Pithampur.

With the acquisition of Pfizer's Morepeth's manufacturing wite in UK, Nicholas Piramal through its wholly owned subsidiary NPIL Pharmaceuticals Limited is a custom manufacturing organization.

NPIL plans to take advantage of the opportunities that will emerge in the bulk actives and intermediates market for contract manufacturing at attractive price points of both on patent and off patent drugs for the regulated markets of Europe, US and Japan. NPIL major investments in R&D which focus on formulations development, new chemical entity research, clinical research from laboratories in India and abroad. The results till now however haven't been very encouraging.

NPIL is the flagship company of the Rs. 2500 crore (US $ 500 million) Piramal Enterprises (PEL). The Group is headed by Mr. Ajay Piramal, who is also the Chairman of NPIL.